Mahnaz Mellati MD

image Mellati, Mahnaz MD for web S2.jpg
Accepting New Patients

Board Certification

American Board of Internal Medicine; Subspecialty Endocrinology, Diabetes and Metabolism

Education

Dr. Mellati received her medical degree from the Qazvin Medical School in Qazvin, Iran. She completed her internship at the Department of Medicine at SUNY Downstate Medical Center in Brooklyn, N.Y. and a residency at the Department of Medicine at Banner University Medical Center in Phoenix, Ariz. She also completed a fellowship in metabolism, endocrinology and nutrition at the University of Washington.

Career Influence

“Throughout medical school and residency, I increasingly became fascinated by the importance of endocrinology in balancing human life. I pursued further specialty training in this field to help those who suffer from these disorders.”

Clinical Interests

Dr. Mellati’s practice encompasses all aspects of endocrinology, with special interest in metabolic bone disease, diabetes, thyroid, parathyroid, pituitary, adrenal and polycystic ovary syndrome disorders as well as transgender care.

Personal Interests

Dr. Mellati enjoys swimming, hiking, skiing, cooking and traveling.

Practice Philosophy

“I believe listening to my patients’ concerns is the key to appropriate testing and accurate diagnosis. I work closely with my patients to educate them about their diseases, giving them all the treatment options and helping them choose the one that fits their individual lifestyle and goals.”

Languages

English and Farsi

Professional Involvement

American Academy of Clinical Endocrinologists
The Endocrine Society

Recognition

Endocrine Society Early Career Forum Travel Award
Endocrine Fellows Series Travel Award

Publications

  • Mellati, M., Eaton, KE., Brooks-Worrell, BM., Hagopian, WA., Martins, R., Palmer, JP., Hirsch, IB. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes Mellitus. Diabetes Care, 2015 Sep;38 (9):e137-8.
  • Meier DT., Entrup L., Templin AT., Hogan MF., Mellati, M., Zraika S., Hull RL., Kahn DE. The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. Diabetologia 2016 Oct;59(10):2166-71.
  • Hogan MD., Meier DT., Zraika S., Templin AT., Mellati M., Hull RL., Leissring MA., Kahn SE., Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro. Endocrinology, 2016 Sep: 157(9):3462-8.